About Vera Therapeutics
Vera Therapeutics is a publicly listed company based in San Francisco (United States) founded in 2016 by Marshall Fordyce. Therapeutic solutions for immunological and inflammatory diseases are developed. Vera Therapeutics has raised $196.58 million across 5 funding rounds from investors including Fidelity Investments, ARE and Kleiner Perkins. The company has 112 employees. Its chief executive, as recorded, is Marshall Fordyce. Its website veratx.com draws about 15 thousand monthly visits. Vera Therapeutics offers products and services including Atacicept. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases. The company has an atacicept novel biologic drug that is a human recombinant fusion protein that helps in treating IgA nephropathy which is a rare autoimmune disease. It contains a soluble TACI receptor that binds to the cytokines BLyS and APRIL to promote B-cell survival and autoantibody production for the treatment of autoimmune diseases.
- Headquarters San Francisco, United States
- Employees 112
- Founders Marshall Fordyce
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website veratx.com
- Social LinkedIn X
- Legal Name Vera Therapeutics, Inc.
- Net Profit-$299.62 M (USD)-96.92as on Dec 31, 2025
- EBITDA-$315 M (USD)-90.91as on Dec 31, 2025
- Total Equity Funding$196.58M (USD)
in 5 rounds
- Latest Funding Round$80M (USD), Series C
Jan 2021
- InvestorsFidelity Investments
& 8 more
- Employee Count112
Products & Services of Vera Therapeutics
Vera Therapeutics offers a comprehensive portfolio of products and services, including Atacicept.
Drug for treating IgA Nephropathy in clinical trials
Funding Insights of Vera Therapeutics
Vera Therapeutics has successfully raised a total of $196.58M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $196.58M
- Total Rounds 5
- Last Round Series C — $80M
- First Round $2.58M
(Apr 2016)
- Investors Count 9
All 5 funding rounds of Vera Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $80M | Series C | – | – | |
| Oct 2020 | $80M | Series C | – | Abingworth | |
| Sep 2019 | $34M | Series B | – | – | |
| Sep 2016 | $1.29M | Grant | – | – | |
| Apr 2016 | $2.58M | Series A | – | – | – |
9 investors in total: 9 institutional.
Investors in Vera Therapeutics
Vera Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ARE and Kleiner Perkins.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
| octagoncg.com | ||||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Vera Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vera Therapeutics
61 people are tracked at Vera Therapeutics (42 in leadership, 7 in board & advisors, 12 in team); the tracked headcount is 112.
| Name | Role | Group |
|---|---|---|
Marshall Fordyce | Founder & CEO | Leadership |
Jeff Weisiger | Executive Sales Director | Leadership |
Paul Safra | Associate Director, Quality Assurance | Leadership |
Ted Egbulefu | Senior Director, Global Commercial Development | Leadership |
David Johnson | Chief Operating Officer | Leadership |
Erin Collins | Senior Director, Clinical Regulatory Affairs | Leadership |
Sean Grant | CFO | Leadership |
Lauren Frenz | Chief Business Officer | Leadership |
Daniel Ramos | Director Talent Acquisition | Leadership |
Alvin L. | Vice President, Commercial Strategy | Leadership |
Raffaella Faggioni | Sr. Vice President | Leadership |
Amy Jia Wang, MPH, MSc | VP, Head of Business Development and Alliance Management | Leadership |
Adam Catherman | Executive Director, Analytical Sciences | Leadership |
Thy Doan, CPA | Associate Director, R&d Finance/accounting | Leadership |
Zherylynn Vinyard | Associate Director | Leadership |
Lauren (Pflepsen) Frenz | Chief Business Officer | Leadership |
Isabel Gorham | Senior Director, Clinical Operations | Leadership |
Melanie Nelson Mha | Senior Director, Patient Support Services And Patient Affordability | Leadership |
Simi Grewal Davis | Senior Director, Commercial Forecasting & Advanced Analytics | Leadership |
Julien E. Capers | VP & Head of Legal | Leadership |
41 more people are available in the full profile.
Complete people profiles for Vera Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vera Therapeutics
Vera Therapeutics is a publicly listed company on the NASDAQ with ticker symbol VERA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 May 2021
- Listed onNASDAQ: VERA
- Listed entityVera Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS92337R1014
- Share price$26.79 (-3.35% on the day) · 2026-10-13
- Market capitalisation$1.93B
- EPS (diluted, trailing year)$-5.87
- Volume (last session)2,990,410
Financials of Vera Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$299.6M | -$315.0M | |
| 2024 | -$152.2M | -$165.0M | |
| 2023 | -$96.0M | -$103.9M | |
| 2022 | -$89.1M | -$91.8M | |
| 2021 | -$32.6M | -$34.1M |
Detailed financial statements for Vera Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Vera Therapeutics
4 dated milestones of Vera Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Vera Therapeutics is founded.
- Funding First funding round of $2.6M.
- Funding Latest funding round, Series C, of $80.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Vera Therapeutics
Vera Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Vera Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vera Therapeutics
The website of Vera Therapeutics (veratx.com) receives about 14.8K visits a month and ranks #1,937,160 among all websites worldwide, #2,639 in Biotechnology and Pharmaceuticals.
- Monthly visits14.8K
▲ 25.5% vs previous month
- Unique visitors6K
per month
- Global rank#1,937,160
among all websites
- Category rank#2,639
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.9
- Average visit53 sec
- DevicesDesktop 51% · Mobile 49%
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Vera Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vera Therapeutics
Complete news archive for Vera Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vera Therapeutics
Vera Therapeutics was founded in 2016.
Vera Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Marshall Fordyce is the CEO of Vera Therapeutics, as recorded in our data. They have also founded this company.
Vera Therapeutics is a funded company, having raised a total of $196.58M across 5 funding rounds to date. The company's 1st funding round was a Series A of $2.58M, raised on Apr 2016.
Vera Therapeutics has 112 employees.
Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases. The company has an atacicept novel biologic drug that is a human recombinant fusion protein that helps in treating IgA nephropathy which is a rare autoimmune disease. It contains a soluble TACI receptor that binds to the cytokines BLyS and APRIL to promote B-cell survival and autoantibody production for the treatment of autoimmune diseases.
Vera Therapeutics's top competitors include ADMA Biologics, Kymeratx and Biogen.
Vera Therapeutics offers Atacicept.
Yes, Vera Therapeutics is publicly traded on NASDAQ under the ticker symbol VERA.
Vera Therapeutics has 9 investors. Key investors include Fidelity Investments, ARE, Kleiner Perkins, HHS, and Abingworth.